All Comparisons
Semaglutide vs Retatrutide
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
Semaglutide: ARetatrutide: B
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / Triple Agonist |
| Evidence Rating | A — FDA Approved | B — Phase III / NDA Filed |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying promoting prolonged fullness, and redu... | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... |
| Half-Life | ~160–168 hours (~7 days) | ~6 days (allows once-weekly dosing) |
| Bioavailability | ~89% SC; lower oral bioavailability (requires empty stomach) | SC injection |
| Molecular Weight | ~4113.6 g/mol | — |
| WADA Status | Not Prohibited | Not Prohibited |
| Dosing | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day, Once weekly (SC); Once daily (oral) (Subcutaneous (weekly injection); Oral tablet available (Rybelsus)) | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3, Once weekly (Subcutaneous (clinical trial formulation only)) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved (Ozempic, Wegovy, Rybelsus). Additional approvals: MASH with fibrosis (Aug 2025), oral 25 mg for weight management (late 2025). 135+ warning letters issued to GLP-1 compounders; proposed permanent ban on 503B GLP-1 compounding. | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.